<DOC>
	<DOCNO>NCT02032524</DOCNO>
	<brief_summary>Primary Objective : Long-term safety pharmacokinetics ( PK ) neoGAA Secondary Objective : Long-term effect neo-GAA pharmacodynamic exploratory efficacy variable</brief_summary>
	<brief_title>NeoGAA Extension Study</brief_title>
	<detailed_description>The duration study 6 year date first patient enters study . Each patient continue study patient withdraws , Investigator withdraws patient , Sponsor terminate study .</detailed_description>
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>Inclusion criterion : Patients Pompe disease previously complete neoGAA study . The patient and/or parent/legal guardian willing able provide sign informed consent , patient , &lt; 18 year age , willing provide assent deem able . The patient ( patient 's legal guardian patient &lt; 18 year age ) must ability comply clinical protocol . The patient , female childbearing potential , must negative pregnancy test [ urine betahuman chorionic gonadotropin ] baseline . Exclusion criterion : The patient concurrently participate another clinical study use investigational treatment . The patient , opinion Investigator , unable adhere requirement study . The patient clinically significant organic disease ( exception symptom relate Pompe disease ) , include clinically significant cardiovascular , hepatic , pulmonary , neurologic , renal disease , medical condition , serious intercurrent illness , extenuate circumstance , opinion Investigator , preclude participation study potentially decrease survival . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>